BD deal surge and policy tailwinds drive China pharma rebound in 2025 BD交易与政策红利共振 医药板块2025年强势反弹
Overseas expansion and BD transactions in innovative drugs have become key catalysts for the sector’s rally, with total outbound licensing and BD deal value surging 161% year on year to $135.7 billion 创新药出海与BD交易成为医药板块股价爆发的重要推动力，创新药BD出海授权全年交易总金额达到1356.55亿美元，较2024年增长161%。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.